DK2601529T3 - Biomarkører til forudsigelse af reaktionen på en cancervaccine - Google Patents
Biomarkører til forudsigelse af reaktionen på en cancervaccine Download PDFInfo
- Publication number
- DK2601529T3 DK2601529T3 DK11749629.9T DK11749629T DK2601529T3 DK 2601529 T3 DK2601529 T3 DK 2601529T3 DK 11749629 T DK11749629 T DK 11749629T DK 2601529 T3 DK2601529 T3 DK 2601529T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer vaccine
- ser
- levels
- patient
- antibodies
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title claims description 113
- 238000009566 cancer vaccine Methods 0.000 title claims description 113
- 230000004044 response Effects 0.000 title claims description 39
- 239000000090 biomarker Substances 0.000 title description 7
- 239000000427 antigen Substances 0.000 claims description 169
- 108091007433 antigens Proteins 0.000 claims description 169
- 102000036639 antigens Human genes 0.000 claims description 169
- 108090000288 Glycoproteins Proteins 0.000 claims description 70
- 102000003886 Glycoproteins Human genes 0.000 claims description 70
- 150000004676 glycans Chemical class 0.000 claims description 64
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 49
- 210000002966 serum Anatomy 0.000 claims description 45
- 241000700605 Viruses Species 0.000 claims description 19
- NPPRJALWPIXIHO-PNCMPRLYSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O NPPRJALWPIXIHO-PNCMPRLYSA-N 0.000 claims description 18
- 102000013361 fetuin Human genes 0.000 claims description 18
- 108060002885 fetuin Proteins 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- ZDZMLVPSYYRJNI-CYQYEHMMSA-N p-lacto-n-hexaose Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1N=C(C)O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)OC([C@@H]1O)CO[C@H]1[C@@H]([C@H](C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1)O)N=C(O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZDZMLVPSYYRJNI-CYQYEHMMSA-N 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 5
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000037830 nasal cancer Diseases 0.000 claims description 4
- 229940030749 prostate cancer vaccine Drugs 0.000 claims description 4
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 68
- 230000004083 survival effect Effects 0.000 description 59
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 28
- 229940098773 bovine serum albumin Drugs 0.000 description 28
- FJGXDMQHNYEUHI-LRFIHEIOSA-N alpha-D-GalNpAc-(1->3)-beta-D-GalpNAc Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O[C@@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 FJGXDMQHNYEUHI-LRFIHEIOSA-N 0.000 description 26
- 239000000523 sample Substances 0.000 description 22
- 230000028993 immune response Effects 0.000 description 21
- 206010060862 Prostate cancer Diseases 0.000 description 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 230000007774 longterm Effects 0.000 description 14
- 150000001720 carbohydrates Chemical class 0.000 description 12
- 235000014633 carbohydrates Nutrition 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 11
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 10
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 239000013610 patient sample Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108700043183 Bos taurus BSM1 Proteins 0.000 description 6
- SFMRPVLZMVJKGZ-JRZQLMJNSA-N Sialyllacto-N-tetraose b Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)O1 SFMRPVLZMVJKGZ-JRZQLMJNSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 108010001517 Galectin 3 Proteins 0.000 description 5
- 102100039558 Galectin-3 Human genes 0.000 description 5
- DINOPBPYOCMGGD-VEDJBHDQSA-N Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 DINOPBPYOCMGGD-VEDJBHDQSA-N 0.000 description 5
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 5
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 5
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 description 5
- IEQCXFNWPAHHQR-YKLSGRGUSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IEQCXFNWPAHHQR-YKLSGRGUSA-N 0.000 description 5
- 239000000412 dendrimer Substances 0.000 description 5
- 229920000736 dendritic polymer Polymers 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 239000000092 prognostic biomarker Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 208000023958 prostate neoplasm Diseases 0.000 description 4
- 229920006048 Arlen™ Polymers 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000700662 Fowlpox virus Species 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 2
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 208000000666 Fowlpox Diseases 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- HUMHYXGDUOGHTG-NCTIFWBYSA-N alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O[C@H]1O HUMHYXGDUOGHTG-NCTIFWBYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 201000003740 cowpox Diseases 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229940031724 lung cancer vaccine Drugs 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 208000005871 monkeypox Diseases 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 229960005030 other vaccine in atc Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229940023147 viral vector vaccine Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RMINQIRDFIBNLE-NNRWGFCXSA-N O-[N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosaminyl]-L-serine Chemical compound O1[C@H](OC[C@H](N)C(O)=O)[C@H](NC(=O)C)[C@@H](O)[C@@H](O)[C@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 RMINQIRDFIBNLE-NNRWGFCXSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940029536 PANVAC Drugs 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- -1 amino- Chemical class 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- FLZWAAFMRTZQGV-ULZIYQADSA-N n-[(2r,3r,4r,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2r,3s,4s,5r)-4,5,6-trihydroxy-1-oxo-2-[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyhexan-3-yl]oxyoxan-3-yl]acetamide Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 FLZWAAFMRTZQGV-ULZIYQADSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Claims (10)
1. Fremgangsmåde til forudsigelse af den kliniske reaktion på en virusbaseret cancervaccine hos en patient med cancer, omfattende at tilvejebringe en serumprøve fra en patient, som ikke tidligere har fået indgivet cancervaccinen; at analysere serumprøven for at bestemme niveauerne af antistoffer hos patienten mod mindst et glycan- og/eller glycoproteinantigen valgt blandt gruppen bestående af Sialyla2-6Gaipi-4Glc-(6'SLac), Sialyla2-3Gaipi-4(Fuca1-3)GlcNAc- (SLeX), Sialyla2-3Ga^1-4Glc- (GM3), Fuca1-2Gaipi-3GlcNAcp1-3Galp1-4Glcp- (BG-H1), ΰθΙΝΑοβΙ^θΙβ- (GA2di), Ga^1-4ΘΙοΝΑοβ1 -6(Ga^1 -4βΙοΝΑοβ1 -3)Ga^- (LNnH), Gala1-3Gal- (Bdi), Ac-Ser-(GalNAca)Thr-Gly-Gly- (Ac-S-Tn(Thr)-G-G), BSM, Laktose, Ga^1-30ΙοΝΑοβ1-3θ8ΐβ-(Ι-ΝΤ), Fuc-b, Fuc-a, Ga^1-6Man-a-(Galb1-6Man-a), Ga^1 -3θ8ΐΝΑοβ1 -4Ga^1 - (GA1), Gala1-4Ga^- (Gala1-4Galb), Manal-6[Mana1 -3]Μ3ηβ- (ManT), Ga^1 -3αοΝΑοβ1 -3Ga^1 -4σΐοΝΑοβ1 -3Ga^1 -(pLNH), Rha-α-, GalNAca1-3Ga^- (Adi), GalNAca1-3(Fuca1-2)Ga^- (BG-A), ΟθΙβΙ^ΟθΙΝΑοβΙ^ΰθΙβΙ- (GA1), fetuin og Ac-Ser-(GalNAca)Ser-Ser-Gly- (Ac-S-Tn(Ser)-S-G); og at sammenligne de bestemte niveauer af antistoffer mod mindst et glycan-og/eller glycoprotei nantigen med en kontrol for at forudsige den kliniske reaktion på cancervaccinen hos patienten.
2. Fremgangsmåde ifølge krav 1, hvor antistofferne er valgt blandt gruppen bestående af IgG, IgM, IgA, IgD, IgE og kombinationer deraf.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor serumprøven analyseres for at bestemme niveauerne af IgM-antistoffer mod BG-A.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1-3, hvor serumprøven analyseres for at bestemme et eller flere af følgende: niveauerne af IgG-antistoffer mod GA1, niveauerne af IgG-antistoffer mod Rha-α, niveauerne af IgA-antistoffer mod Fuc-a, niveauerne af lg-antistoffer mod LNnH, niveauerne af IgG-antistoffer mod 6'SLac og niveauerne af IgG-antistoffer mod GM3.
5. Anvendelse af en sammmensætning, der indbefatter mindst et glycan- og/ eller glycoproteinantigen valgt blandt gruppen bestående af Sialyla2-6Gal(S1-4Glc-(6'SLac), Sialyla2-3Gaipi-4(Fuca1 -3)GlcNAc- (SLeX), Sialyla2-3Galp1-4Glc-(GM3), Fuca1-2Galp1-3GlcNAcp1-3Galp1-4Glcp-(BG-H1), GalNAcpi-4Galp-(GA2di), Galp1-4GlcNAcp1-6(Gal31-4GlcNAc31-3)Gal3- (LNnH), Gala1-3Gal-(Bdi), Ac-Ser-(GalNAca)Thr-Gly-Gly- (Ac-S-Tn(Thr)-G-G), BSM, Laktose, Galpl-3GlcNAcpi-3Gaip-(LNT), Fuc-b, Fuc-a, Gaipi-6Man-a- (Galb1-6Man-a), Ga^1-3GalNAc31-4Galp1- (GA1), Galcd-4Galp- (Gala1-4Galb), Mana1-6[Mana1-3]Manp- (ManT), Galp1-3GlcNAc31-3Gal31-4GlcNAc31-3Ga^1- (pLNH), Ftha-α-, GalNAca1-3Galp- (Adi), GalNAca1-3(Fuca1-2)Galp- (BG-A), Gaipi-3GalNAc31-4Galp1- (GA1) og Ac-Ser-(GalNAca)Ser-Ser-Gly-(Ac-S-Tn(Ser)-S-G) til at forudsige den kliniske reaktion på en virusbaseret cancervaccine hos en patient som defineret i krav 1.
6. Fremgangsmåde ifølge krav 1, hvor niveauerne af antistoffer hos patienten mod GalNAca1-3(Fuca1-2)Ga^- (BG-A) bestemmes og sammenlignes med en kontrol.
7. Fremgangsmåde ifølge krav 6, hvor den virusvektorbaserede cancervaccine er en koppevirusbaseret cancervaccine.
8. Fremgangsmåde ifølge krav 6 eller 7, hvor den virusvektorbaserede cancervaccine er en prostatacancervaccine, brystcancervaccine, pancreatisk cancervaccine, ovariecancervaccine, gastrisk cancervaccine, hoved-halscancervaccine, levercancervaccine, lungecancervaccine, nyrecancervaccine, knoglecancer-vaccine, hjernecancervaccine, kolorektal cancervaccine, livmodercancervaccine, hudcancervaccine, endometriecancervaccine, øsofaguscancervaccine, anal-cancervaccine, mundcancervaccine, næsecancervaccine eller rektalcancer-vaccine.
9. Fremgangsmåde ifølge krav 8, hvor den virusvekstorbaserede cancervaccine er en prostatacancervaccine.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 6-9, der endvidere omfatter at analysere serumprøven for at bestemme niveauerne af antistoffer hos en patient mod mindst et glycan- og/eller glycoproteinantigen valgt blandt gruppen bestående af Sialyla2-6Galp1-4Glc-(6'SLac), Sialyla2-3Galp1-4(Fuca1-3)GlcNAc- (SLeX), Sialyla2-3Galp1 -4Glc- (GM3), Fuca1-2Gal|31-3GlcNAcp1-3Galp1-4Glcp- (BG-H1), GalNAcp1-4Ga^- (GA2di), Galp1-4GlcNAcp1-6(Galp1-4GlcNAc31-3)Gaip- (LNnFI), Gala1-3Gal- (Bdi), Ac-Ser-(GalNAca)Thr-Gly-Gly-(Ac-S-Tn(Thr)-G-G), BSM, Laktose, Galp1-3GlcNAcp1-3Gal3-(LNT), Fuc-b, Fuc-a, Galpi-6Man-a-(Galb1 -6Man-a), Gal31-3GalNAcp1-4Gal31- (GA1), Galcrl-4Gaip- (Gala1-4Galb), Måned-6[Mana1-3]Manp- (ManT), Gaipi-3GlcNAcpi-3Gaipi -4βΙοΝΑοβ1 -3Ga^1 - (pLNH), Rha-α-, GalNAca1-3Ga^- (Adi), Ga^1-3GalNAcp1-4Galp1- (GA1), fetuin og Ac-Ser-(GalNAca)Ser-Ser-Gly- (Ac-S-Tn(Ser)-S-G); og at sammenligne de bestemte niveauer af antistoffer mod mindst et glycan- og/eller glycoprotei nantigen med en kontrol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37153710P | 2010-08-06 | 2010-08-06 | |
| US201161443955P | 2011-02-17 | 2011-02-17 | |
| PCT/US2011/046799 WO2012019125A2 (en) | 2010-08-06 | 2011-08-05 | Biomarkers for prostate cancer and methods for their detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2601529T3 true DK2601529T3 (da) | 2017-03-27 |
Family
ID=45560097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11749629.9T DK2601529T3 (da) | 2010-08-06 | 2011-08-05 | Biomarkører til forudsigelse af reaktionen på en cancervaccine |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9804163B2 (da) |
| EP (2) | EP2601529B8 (da) |
| AU (2) | AU2011285534B2 (da) |
| CA (1) | CA2807514A1 (da) |
| DK (1) | DK2601529T3 (da) |
| WO (1) | WO2012019125A2 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6505713B2 (ja) * | 2013-09-05 | 2019-04-24 | デンドレオン ファーマシューティカルズ インコーポレイテッド | 癌抗原特異的能動免疫療法による処置後の腫瘍抗原に対する液性免疫応答およびその改善された臨床結果との関連性 |
| JP2020524809A (ja) * | 2017-06-23 | 2020-08-20 | オンシミューン ジャーマニー ジーエムビーエイチ | がんを治療するためのがん免疫 |
| KR102019676B1 (ko) * | 2018-02-02 | 2019-09-11 | 상지대학교산학협력단 | 시아릴락토오스(Sialyllactose)를 포함하는 전립선 비대 질환 예방 또는 치료용 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0700445T3 (da) | 1993-06-04 | 2002-05-13 | Whitehead Biomedical Inst | Stressproteiner og anvendelser deraf |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| DE69519521T2 (de) | 1994-10-03 | 2001-06-28 | Us Gov Nat Inst Health | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
| US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| US6165460A (en) | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| US6946133B1 (en) | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
| AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
| CA2282300C (en) | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US20070048860A1 (en) | 1997-10-10 | 2007-03-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Carcinoembryonic antigen (CEA) peptides |
| JP2004534088A (ja) | 2001-07-06 | 2004-11-11 | スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ | 癌のための多価コンジュゲートワクチン |
| JP2008539412A (ja) | 2005-04-26 | 2008-11-13 | レイモンド， エー． ドウェック， | 癌の診断及びモニタリングのためのグリコシル化マーカー |
| US7892752B2 (en) | 2005-04-26 | 2011-02-22 | Dwek Raymond A | Glycosylation markers for cancer diagnosing and monitoring |
| WO2009035494A2 (en) * | 2007-07-30 | 2009-03-19 | The Scripps Research Institute | Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease |
| US8383767B2 (en) * | 2008-06-27 | 2013-02-26 | Academia Sinica | Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain |
-
2011
- 2011-08-05 WO PCT/US2011/046799 patent/WO2012019125A2/en active Application Filing
- 2011-08-05 US US13/814,337 patent/US9804163B2/en not_active Expired - Fee Related
- 2011-08-05 EP EP11749629.9A patent/EP2601529B8/en not_active Not-in-force
- 2011-08-05 AU AU2011285534A patent/AU2011285534B2/en not_active Ceased
- 2011-08-05 CA CA2807514A patent/CA2807514A1/en not_active Abandoned
- 2011-08-05 DK DK11749629.9T patent/DK2601529T3/da active
- 2011-08-05 EP EP16199473.6A patent/EP3153861A3/en not_active Withdrawn
-
2016
- 2016-03-09 AU AU2016201526A patent/AU2016201526B2/en not_active Ceased
- 2016-11-08 US US15/345,634 patent/US20170052185A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3153861A2 (en) | 2017-04-12 |
| US20170052185A1 (en) | 2017-02-23 |
| WO2012019125A3 (en) | 2012-08-16 |
| AU2016201526A1 (en) | 2016-03-24 |
| AU2016201526B2 (en) | 2017-10-19 |
| EP2601529A2 (en) | 2013-06-12 |
| EP3153861A3 (en) | 2017-06-07 |
| EP2601529B8 (en) | 2017-01-25 |
| AU2011285534B2 (en) | 2015-12-17 |
| US20130156813A1 (en) | 2013-06-20 |
| CA2807514A1 (en) | 2012-02-09 |
| EP2601529B1 (en) | 2016-12-21 |
| AU2011285534A1 (en) | 2013-02-21 |
| US9804163B2 (en) | 2017-10-31 |
| WO2012019125A2 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102336968B1 (ko) | 자연적으로 처리된 hla-제한 암 펩티드의 절대 정량 방법 | |
| Krug et al. | Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin | |
| JP6612414B2 (ja) | Ｐｄ−ｌ１に対するｓｒｍアッセイ | |
| JP2008503494A (ja) | 診断方法を治療方法と統合することによる免疫療法の効力改善 | |
| JP2002530629A (ja) | 癌診断インジケータとしてのｎ末端切断型ｈｅｒ−２／ｎｅｕ蛋白質 | |
| AU2016201526B2 (en) | Biomarkers for prostate cancer and methods for their detection | |
| US20140274768A1 (en) | Glycoforms of MUC5AC and Endorepellin and Biomarkers for Mucinous Pancreatic Cysts | |
| EP2081649A2 (en) | Modulation of cd1b or cd1d expression in autoimmune disorders | |
| JP6172687B2 (ja) | シアリル化糖鎖を認識するモノクローナル抗体 | |
| KR20200016242A (ko) | T-dm1에 의한 암 치료 결과의 예측 | |
| WO2011025542A1 (en) | Seromic analysis of ovarian cancer | |
| CN108379568B (zh) | 一种抵抗素多肽疫苗及其在治疗乳腺癌中的应用 | |
| EP2800580B1 (en) | Peptides for use in treating or diagnosing idh1 r132h positive cancers | |
| CN107847866A (zh) | 细胞周期蛋白依赖性激酶抑制剂2A(p16)的SRM/MRM测定 | |
| RU2010149266A (ru) | Улучшенные способы иммуноанализа | |
| Nagata et al. | Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy | |
| US10345308B2 (en) | Human serum biomarkers of prostate cancer and SARS-CoV | |
| CN109513002B (zh) | 缓解发炎的tn疫苗及方法 | |
| KR101825644B1 (ko) | Nedd4-1 단백질의 발현 수준을 측정하는 물질을 포함하는 자궁경부암 진단용 조성물 및 이를 이용한 자궁경부암 진단을 위한 정보제공방법 | |
| KR20230165283A (ko) | 암을 위한 바이오마커 및 요법 표적으로서의 시트룰린화된 단백질 | |
| EP2876442A1 (en) | Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer | |
| CN108226524A (zh) | 一种基于双分子荧光互补技术的cTnT检测试剂盒、制备及使用方法 | |
| WO2015133974A1 (en) | Usage of antibodies in diagnosing cancer cells | |
| July | Human serum biomarkers of prostate cancer and SARS-CoV | |
| Schiffman | Clinical Translation of Peptide-Based Vaccine Trials: The HER-21neu Model |